Rheumatology (Oxford, England) · 2026
Time-varying cardiovascular risk of febuxostat vs. allopurinol in gout: a one-stage meta-analysis.
СтатьяМетаанализСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wei Qige, Shi Yang, Hu Rui, Wang Hui, Li Yan, Luo Li, Shao Dan, Zhao Jianglin, Zhang Shengzhao
Аннотация
OBJECTIVES: Whether febuxostat is associated with an increased cardiovascular risk compared with allopurinol in patients with gout remains controversial, with major randomized trials reporting conflicting results. This study aims to perform a comprehensive meta-analysis using reconstructed individual participant data (IPD) to evaluate the time-varying cardiovascular and mortality risk of febuxostat vs. allopurinol in gout.
METHODS: We conducted a one-stage individual participant data meta-analysis. PubMed, Embase and Cochrane Library were searched up to November 2025 for randomized controlled trials and propensity score-matched observational studies reporting Kaplan-Meier curves for cardiovascular risk or all-cause mortality. Individual patient data were reconstructed from published curves. Time-varying hazard ratios (HRs) were estimated using a mixed-effects Cox model with treatment-by-time interaction across pre-specified intervals (0-12, 12-24, 24-48, >48 months).
RESULTS: Four studies (n = 19 090) were included. Analysis revealed significant time-varying effects. For cardiovascular risk, HRs were 0.89 (95% CI 0.79-0.99) at 0-12 months, 0.58 (0.50-0.68) at 12-24 months, 0.86 (0.74-0.99) at 24-48 months and 1.09 (0.81-1.46) after >48 months. For all-cause mortality, HRs were 0.70 (0.62-0.79), 0.39 (0.33-0.45), 0.75 (0.65-0.86) and 1.02 (0.77-1.34) across the same intervals, respectively.
CONCLUSION: The cardiovascular and mortality risk of febuxostat relative to allopurinol is time-dependent, showing a significant early reduction that attenuates over time. These findings advocate for a time-aware approach to clinical management and monitoring.
METHODS: We conducted a one-stage individual participant data meta-analysis. PubMed, Embase and Cochrane Library were searched up to November 2025 for randomized controlled trials and propensity score-matched observational studies reporting Kaplan-Meier curves for cardiovascular risk or all-cause mortality. Individual patient data were reconstructed from published curves. Time-varying hazard ratios (HRs) were estimated using a mixed-effects Cox model with treatment-by-time interaction across pre-specified intervals (0-12, 12-24, 24-48, >48 months).
RESULTS: Four studies (n = 19 090) were included. Analysis revealed significant time-varying effects. For cardiovascular risk, HRs were 0.89 (95% CI 0.79-0.99) at 0-12 months, 0.58 (0.50-0.68) at 12-24 months, 0.86 (0.74-0.99) at 24-48 months and 1.09 (0.81-1.46) after >48 months. For all-cause mortality, HRs were 0.70 (0.62-0.79), 0.39 (0.33-0.45), 0.75 (0.65-0.86) and 1.02 (0.77-1.34) across the same intervals, respectively.
CONCLUSION: The cardiovascular and mortality risk of febuxostat relative to allopurinol is time-dependent, showing a significant early reduction that attenuates over time. These findings advocate for a time-aware approach to clinical management and monitoring.